IDEXX LABORATORIES INC /DE

IDXX · XNAS

CIK 874716fmd_0FA3CPQEA7MPDK77XX3QEX795TManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	1,775	1,969	2,213	2,407	2,707	3,215	3,367	3,661	3,898	4,304
Cost of revenue	800	872	972	1,041	1,136	1,326	1,363	1,471	1,519	1,644
Gross profit	975	1,097	1,242	1,366	1,571	1,889	2,004	2,190	2,379	2,660
Provision for credit losses	–	–	–	1	5	1	6	6	7	8
Research and development	101	109	118	133	141	161	255	191	220	251
Selling, general and administrative	524	575	632	680	735	796	851	902	1,031	1,048
Total operating expenses	–	–	750	–	–	–	1,106	1,093	1,251	1,300
Operating income	350	413	491	553	695	932	899	1,097	1,128	1,360
Interest expense	32	37	35	31	33	30	40	42	31	39
Interest and investment income	4	5	1	0	1	0	1	6	13	3
Income before taxes	322	381	458	522	662	903	860	1,061	1,110	1,324
Income tax expense	100	118	81	94	80	158	181	216	222	265
Net income from continuing operations	222	263	377	428	582	745	679	845	888	1,059
Net income	222	263	377	428	582	745	679	845	888	1,059